Metabolic HealthGLP-1 Drugs Cut Limb Loss and Death Risk in Diabetic Artery Disease Patients
Peripheral artery disease combined with diabetes creates a dangerous duo — dramatically raising the risk of limb amputations and death. This Israeli retrospective study of over 20,000 patients examined whether GLP-1 receptor agonists (drugs like semaglutide and liraglutide) offer protection beyond their known heart benefits. Researchers found that patients using GLP-1 drugs had significantly lower rates of major adverse limb events, including amputations and revascularization procedures, as well as lower all-cause mortality. Sustained use of GLP-1 drugs was particularly protective, cutting the hazard of serious limb complications by 35%. The mortality benefit held up even after applying rigorous statistical methods to reduce bias. While this is observational data and causality cannot be confirmed, the findings add to a growing body of evidence supporting broader protective effects of GLP-1 receptor agonists in high-risk vascular disease populations.
